PreveCeutical files provisional patent application in Australia seeking protection for cannabinoid formulations to prevent and treat COVID-19

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FRA:18H) has filed a provisional patent application in Australia with the aim of seeking protection for certain cannabinoid formulations to prevent and treat the COVID-19 disease caused by the SARS-CoV-2 virus.  "This patent is a very important patent addition to our library of intellectual properties (IP),” said CEO Stephen Van Deventer in a statement Monday. “The provisional application filing for this application will protect our cannabinoid Sol-gel IP as we prepare for clinical trials and commercialization of this formulation."  The Vancouver-based company said it is not making any express or implied claims that its product has the ability to eliminate, cure, or contain COVID-19 at this time.  READ: PreveCeutical Medical advancing its coronavirus (COVID-19) Cannabinoid Sol-Gel Program The application, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use," was filed on November 20 with the Australian Patent Office. Amid the coronavirus pandemic, PreveCeutical and its Australian partner are now developing a sol-gel CBD formula. With the use of a nose applicator, the sustained-released Sol-Gel formulations allows for the direct and prolonged delivery of cannabinoids to a patient's central nervous system. The program is designed to prevent SARS-CoV-2 infection in nasal tissue. PreveCeutical also has developed Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham